KALV Long Put Strategy
KALV (KalVista Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV (KalVista Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.37B, a beta of -0.12 versus the broader market, a 52-week range of 9.83-26.85, average daily share volume of 2.8M, a public-listing history dating back to 2015, approximately 150 full-time employees. These structural characteristics shape how KALV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.12 indicates KALV has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on KALV?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current KALV snapshot
As of May 14, 2026, spot at $26.77, ATM IV 36.30%, IV rank 10.16%, expected move 10.41%. The long put on KALV below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this long put structure on KALV specifically: KALV IV at 36.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a KALV long put, with a market-implied 1-standard-deviation move of approximately 10.41% (roughly $2.79 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KALV expiries trade a higher absolute premium for lower per-day decay. Position sizing on KALV should anchor to the underlying notional of $26.77 per share and to the trader's directional view on KALV stock.
KALV long put setup
The KALV long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KALV near $26.77, the first option leg uses a $26.77 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KALV chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KALV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $26.77 | N/A |
KALV long put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
KALV long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on KALV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long put on KALV
Long puts on KALV hedge an existing long KALV stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying KALV exposure being hedged.
KALV thesis for this long put
The market-implied 1-standard-deviation range for KALV extends from approximately $23.98 on the downside to $29.56 on the upside. A KALV long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long KALV position with one put per 100 shares held. Current KALV IV rank near 10.16% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KALV at 36.30%. As a Healthcare name, KALV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KALV-specific events.
KALV long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KALV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KALV alongside the broader basket even when KALV-specific fundamentals are unchanged. Long-premium structures like a long put on KALV are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current KALV chain quotes before placing a trade.
Frequently asked questions
- What is a long put on KALV?
- A long put on KALV is the long put strategy applied to KALV (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With KALV stock trading near $26.77, the strikes shown on this page are snapped to the nearest listed KALV chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are KALV long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the KALV long put priced from the end-of-day chain at a 30-day expiry (ATM IV 36.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a KALV long put?
- The breakeven for the KALV long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KALV market-implied 1-standard-deviation expected move is approximately 10.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on KALV?
- Long puts on KALV hedge an existing long KALV stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying KALV exposure being hedged.
- How does current KALV implied volatility affect this long put?
- KALV ATM IV is at 36.30% with IV rank near 10.16%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.